Hoffmann-la Roche Inc.

Merck Sharp + Dohme Corp.

F. Hoffmann-la Roche Ag

Eric Mertz

Sung-Sau So

Scott D Edmondson

Amjad Ali

Shawn David Erickson

Fariborz Firooznia

Paul Gillespie

Ying-Duo Gao

Santhosh Francis Neelamkavil

Wanying Sun

Weiguo Liu

Tai-An Lin

Zhi Chen

Achyutharao Sidduri

Elbert Chin

Alan W Hruza

Robert James Weikert

Stephen Deems Gabriel

Jiafang He

Joseph Anthony Bilotta

Jefferson Wright Tilley

Yimin Qian

Jean-Marc Plancher

Zhuyan Guo

Nancy-Ellen Haynes

Rongze Kuang

Anthony K Ogawa

Qingjie Ding

Linda Brockunier

Kevin Richard Guertin

Adrian Wai-Hing Cheung

Kshitij Chhabilbhai Thakkar

Buelent Kocer

Heping Wu

Jenny Tan

Yi Zang

Lida Qi

Feng Chi

Li Chen

Dong-Ming Shen

Yun He

Hongying Yun

Francisco Javier Lopez-Tapia

Cheng Zhu

Romyr Dominique

Yeon-Hee Lim

Wei Zhou

Jiayi Xu

Jing Zhang

Steven Joseph Berthel

Nan Jiang

Thomas A Bara

Nathan Robert Scott

Bart Harper

Meng Yang

Ning Shao

Remond Moningka

Rudrajit Mal

Zhenshan Zhang

Qiang Zhang

Stuart Hayden

Nicholas Marcopulos

Han Ma

Christine M Lukacs-Lesburg

JohnMark Derryberry

Robert J Weikert

David Shawn Erickson

Andrew F Nolting

Francisco Javier Lopez-tapia

Linda L Brockunier

Thomas Bara

Klaus Klumpp

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma Kallikrein. 

Factor XIA inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention provides a compound of Formula (I) (Formula (I)) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

Antiviral compounds

The present invention provides a compound of Formula I (The chemical formula should be inserted here.) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor Xla inhibitors

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection. 

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection. 

The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.

This application discloses compounds according to generic Formula (I): wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient. 

Inhibitors of Bruton's tyrosine kinase

The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer. 

Substituted isoxazole amide compounds as inhibitors of stearoyl-CoA desaturase 1 (SCD1)

The invention is concerned with a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament. 

Substituted isoxazole amine compounds as inhibitors of SCD1

The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R, R, Rand X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

Substituted naphthylacetic acids

Piperidinyl naphthylacetic acids

Growing community of inventors

Fair Lawn, NJ, United States of America

Eric Mertz